# Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival

> **NCT07731425** · NA · NOT_YET_RECRUITING · sponsor: **London School of Economics and Political Science** · enrollment: 3000 (estimated)

## Conditions studied

- Cancer

## Interventions

- **OTHER:** FDA explanation for progression-free survival (control)
- **OTHER:** FDA explanation for progression-free survival with overall survival data
- **OTHER:** NCI explanation for progression-free survival
- **OTHER:** NCI explanation for progression-free survival with overall survival data
- **OTHER:** Plain-language explanation of progression-free survival
- **OTHER:** Plain-language explanation of progression-free survival with overall survival data

## Key facts

- **NCT ID:** NCT07731425
- **Lead sponsor:** London School of Economics and Political Science
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07731425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07731425, "Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07731425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*